Novartis AG (MEX:NVSN) Short-Term Debt: MXN167,301 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:NVSN Novartis AG MEX:NVSN
70 GF Score
Price MXN2,677.00
GF Value MXN2,262.21
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG Short-Term Debt?

Novartis AG MEX:NVSN -1.22% 70 Short-Term Debt is MXN167,301 Mil as of Jun. 2026. GuruFocus rates MEX:NVSN with a GF Score™ of 70/100 and a GF Value™ of MXN2,262.21 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Novartis AG's Short-Term Debt for the quarter that ended in Jun. 2026 was MXN167,301 Mil.

Novartis AG's quarterly Short-Term Debt increased from Dec. 2025 (MXN99,409 Mil) to Mar. 2026 (MXN137,355 Mil) and increased from Mar. 2026 (MXN137,355 Mil) to Jun. 2026 (MXN167,301 Mil).

Novartis AG's annual Short-Term Debt increased from Dec. 2023 (MXN103,271 Mil) to Dec. 2024 (MXN168,702 Mil) but then declined from Dec. 2024 (MXN168,702 Mil) to Dec. 2025 (MXN99,409 Mil).

Novartis AG Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Novartis AG Short-Term Debt Related Terms

Novartis AG Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Novartis AG's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Short-Term Debt Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 127,740.68 114,558.50 103,271.33 168,701.76 99,409.47

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 156,545.97 137,948.38 99,409.47 137,355.08 167,301.01
MEX:NVSN
70GF Score
Novartis AG MEX:NVSN
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of MXN167,301 Mil mean?
Novartis AG (MEX:NVSN) has a Short-Term Debt of MXN167,301 Mil as of Jun. 2026.
Is Novartis AG's Short-Term Debt too high?
Novartis AG's current Short-Term Debt is MXN167,301 Mil. Overall, Novartis AG has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Short-Term Debt compare to LLY and JNJ?
Novartis AG's Short-Term Debt of MXN167,301 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Novartis AG's current Short-Term Debt is MXN167,301 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (MEX:NVSN) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN2,262.21, compared to a current price of MXN2,677.00 — trading 18.3% above its estimated fair value. The current Short-Term Debt is MXN167,301 Mil. Novartis AG's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Novartis AG (MEX:NVSN), the current Short-Term Debt is MXN167,301 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (MEX:NVSN) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of MXN2,677.00 is trading 18.3% above its estimated GF Value™ of MXN2,262.21. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for MEX:NVSN:

  • Short-Term Debt: MXN167,301 Mil
  • GF Value™: MXN2,262.21 vs. price of MXN2,677.00 (18.3% above fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the MEX:NVSN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
70GF Score

Get the complete analysis for MEX:NVSN

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,677.00
Price
MXN2,262.21
GF Value